コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 condary progressive than in those who remain relapsing remitting multiple sclerosis.
2 ects of IFN-beta therapy in the treatment of relapsing remitting multiple sclerosis.
3 ing lesions on magnetic resonance imaging in relapsing remitting multiple sclerosis.
4 trial of estriol is warranted in women with relapsing remitting multiple sclerosis.
5 t approved oral therapy for the treatment of relapsing remitting multiple sclerosis.
6 lications for the diagnosis and treatment of relapsing remitting multiple sclerosis.
7 ins the most widely prescribed treatment for relapsing remitting multiple sclerosis.
8 ormalities between secondary progressive and relapsing remitting multiple sclerosis.
9 rolled phase 3 study involving patients with relapsing-remitting multiple sclerosis.
10 ebo-controlled study involving patients with relapsing-remitting multiple sclerosis.
11 y, as compared with placebo in patients with relapsing-remitting multiple sclerosis.
12 s aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis.
13 trial of previously untreated patients with relapsing-remitting multiple sclerosis.
14 tivity in previously untreated patients with relapsing-remitting multiple sclerosis.
15 reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.
16 in a Phase I/IIa clinical trial in new-onset relapsing-remitting multiple sclerosis.
17 -course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
18 s highly effective in the treatment of early relapsing-remitting multiple sclerosis.
19 and Crohn's disease but a negative result in relapsing-remitting multiple sclerosis.
20 B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
21 encephalomyelitis (EAE), an animal model of relapsing-remitting multiple sclerosis.
22 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.
23 ing very late antigen-4 for the treatment of relapsing-remitting multiple sclerosis.
24 ve Th cell clone derived from a patient with relapsing-remitting multiple sclerosis.
25 l simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis.
26 yelitis and reduces the relapse frequency in relapsing-remitting multiple sclerosis.
27 ne may provide a novel therapeutic agent for relapsing-remitting multiple sclerosis.
28 unction rather than loss in clinically early relapsing-remitting multiple sclerosis.
29 esion probability maps from 19 patients with relapsing-remitting multiple sclerosis.
30 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.
31 rferon beta-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.
32 d for the treatment of people suffering from relapsing-remitting multiple sclerosis.
33 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.
34 lockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis.
35 erapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.
36 ing agent in the management of patients with relapsing-remitting multiple sclerosis.
37 al effects on relapse rates in patients with relapsing-remitting multiple sclerosis.
38 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.
39 the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.
40 al and MRI disease activity in patients with relapsing-remitting multiple sclerosis.
41 ort further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis.
42 mmunomodulator approved for the treatment of relapsing-remitting multiple sclerosis.
43 ephalomyelitis (EAE) that mirror chronic and relapsing-remitting multiple sclerosis.
44 more efficacious than either agent alone in relapsing-remitting multiple sclerosis.
45 response to interferon beta in patients with relapsing-remitting multiple sclerosis.
46 od reduces disease activity in patients with relapsing-remitting multiple sclerosis.
47 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.
48 ation due to adverse events in patients with relapsing-remitting multiple sclerosis?
50 -progressive (49.3 +/- 8.0 mM) compared with relapsing-remitting multiple sclerosis (43.0 +/- 8.5 mM,
51 trial of annual alemtuzumab for treatment of relapsing-remitting multiple sclerosis, 6 of 216 patient
52 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro
53 In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, p
54 l trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety
56 atients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab coul
58 ross-sectional study of 41 patients, 21 with relapsing-remitting multiple sclerosis and 20 with secon
59 000 ms, nominal voxel volume 2.3 ml) from 27 relapsing-remitting multiple sclerosis and 29 normal con
60 al, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one
61 resonance imaging at 3 T in 17 patients with relapsing-remitting multiple sclerosis and in 13 normal
62 and white matter atrophy in clinically early relapsing-remitting multiple sclerosis and its relations
63 Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had complete
64 n of interferon-beta's therapeutic effect in relapsing-remitting multiple sclerosis, and has implicat
65 fluid samples of patients with encephalitis, relapsing-remitting multiple sclerosis, and other neurol
66 ears old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive
67 atents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, cre
68 their effects on disability in patients with relapsing-remitting multiple sclerosis are maintained an
72 ging has been examined in small cohorts with relapsing-remitting multiple sclerosis, but has not been
73 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy
74 and North America reduce the relapse rate in relapsing/remitting multiple sclerosis by about 30%.
75 rimary and secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -
76 ratio values in the outer cord were lower in relapsing-remitting multiple sclerosis compared with cli
77 onse to CRH was greater in the patients with relapsing-remitting multiple sclerosis compared with the
78 rs was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2.89
80 at the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a
82 DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the U
83 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil
84 ed cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing rela
85 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one
86 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres i
88 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a
90 progressive multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these
92 3 years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years dise
94 terferons and glatiramer in the treatment of relapsing-remitting multiple sclerosis has been advanced
95 tive disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been license
96 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no
97 s use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit
98 igher in secondary-progressive compared with relapsing-remitting multiple sclerosis in cortical grey
99 ,E,A,K)n] is widely used in the treatment of relapsing/remitting multiple sclerosis in which it reduc
100 , which is currently used as a treatment for relapsing, remitting multiple sclerosis, is a potent imm
102 tissue sodium concentration in patients with relapsing-remitting multiple sclerosis might reflect cha
103 Second, PBL obtained from patients with relapsing/remitting multiple sclerosis mount a prolifera
106 immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the Unite
107 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influence
108 pinal fluid (CSF) samples from patients with relapsing-remitting multiple sclerosis (MS) obtained wit
110 on medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in
111 f anti-OSP Abs in the cerebrospinal fluid of relapsing-remitting multiple sclerosis (MS) patients, bu
112 reduces the frequency of relapses by 30% in relapsing-remitting multiple sclerosis (MS) patients.
115 c stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not
116 uperior efficacy over interferon beta-1a for relapsing-remitting multiple sclerosis (MS), and is curr
123 ts with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progr
125 In a pilot trial, oral estriol treatment of relapsing remitting multiple sclerosis patients caused s
126 nd extra-cellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 h
127 xonal analysis could define axonal damage in relapsing-remitting multiple sclerosis patients earlier
128 III multi-center trial of oral myelin in 515 relapsing-remitting multiple sclerosis patients is in pr
129 gn, peripheral blood was obtained from eight relapsing-remitting multiple sclerosis patients just bef
130 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu
132 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence
133 disagreement among devices in patients with relapsing-remitting multiple sclerosis regarding the ON
134 inical trial of simvastatin in patients with relapsing remitting multiple sclerosis (RR MS), which de
136 an CSF, and was compared among subjects with relapsing-remitting multiple sclerosis (RR-MS; n = 52),
137 ntegrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other
138 Foxp3(+) T cells in untreated subjects with relapsing remitting multiple sclerosis (RRMS) as compare
139 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe
140 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a
142 TCR stimulation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of
143 umab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe,
145 mbulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or seconda
146 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a
147 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e
150 osis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed tha
151 stekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess
152 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzum
153 atiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no pu
154 le SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laqu
155 In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORM
164 ion with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study,
165 ion With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and I
166 a T cell receptor (TCR) from a patient with relapsing-remitting multiple sclerosis that engages its
167 oncentric sclerosis and in a subset of early relapsing remitting multiple sclerosis, the initial myel
168 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu
169 s, and more so in secondary progressive than relapsing remitting multiple sclerosis, tissue structura
170 , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare dacliz
171 ligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingol
172 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to
175 d, 48-week trial involving 104 patients with relapsing-remitting multiple sclerosis, we assigned 69 p
178 d Disability Status Score (EDSS) 0-7.5] with relapsing-remitting multiple sclerosis were selected on
179 autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered
180 ) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonl
181 udy, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a recent
183 a woman in her late 30s with a diagnosis of relapsing-remitting multiple sclerosis, who continued to
184 The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequen
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。